Delivering the Added Dimension in Drug Discovery Services
Drug discovery is a complex process that requires cross-functional scientific expertise and knowledge in disease biology. Jubilant’s understanding of disease biology is constantly evolving with every program that we execute, and with emerging literature and new technologies, investigations that were deemed unviable in the past are now possible. One has to cautiously and continuously apply this knowledge in the drug hunting process to be successful in drug discovery in a timely manner.
Jubilant Biosys has invested in Science and Technology and we have built an Integrated Drug Discovery site with cross-functional expertise in discovery informatics, computational chemistry, medicinal chemistry, protein sciences, structural biology, assay biology, disease biology & pharmacology, DMPK & toxicology. We work on a variety of therapeutic areas including metabolic disorders, inflammation, oncology & Pain and we have conducted more than 75+ Integrated Drug Discovery programs with Biotech and Pharma partners to date. Our specialization is small molecule drug discovery and we have technology platforms to prosecute proteins, DNA, and RNA as drug targets.
Our customers include VC funded early-stage Biotechs, mid-size and large Pharma and Biotechs. We engage with our customers starting from early-stage target ideation, all the way through IND enabling studies to deliver a candidate. The Webinar will focus on the Integrated Drug Discovery capabilities of Jubilant Biosys and specifically, we will talk about our experience of working on Target to Candidate drug discovery for Biotechs and Pharma partners.
Saravanakumar Dhakshinamoorthy, PhD
Vice President, Discovery Biology – Jubilant Biosys Limited
Saravanakumar (SK) has 20 years of experience in discovery biology & pharmacology. SK has worked at leading drug discovery organizations and has held positions of increasing responsibility. SK has managed integrated drug discovery collaborations with big pharma and biotech companies across the United States, Europe & Asia that has led to candidate compounds for clinical development.